<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01707407</url>
  </required_header>
  <id_info>
    <org_study_id>CC-4047-CP-008</org_study_id>
    <nct_id>NCT01707407</nct_id>
  </id_info>
  <brief_title>A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects</brief_title>
  <acronym>DDI</acronym>
  <official_title>A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the pharmacokinetics (PK) of pomalidomide administered with the CYP3A4/P-gp&#xD;
           inhibitor ketoconazole compared with pomalidomide alone in healthy male subjects.&#xD;
&#xD;
        2. To evaluate the PK of pomalidomide administered with the CYP3A4/P-gp inhibitor&#xD;
           ketoconazole plus the CYP1A2 inhibitor fluvoxamine compared with pomalidomide alone in&#xD;
           healthy male subjects.&#xD;
&#xD;
        3. To assess the PK of pomalidomide administered with the CYP1A2 inhibitor fluvoxamine and&#xD;
           the CYP3A4/P-gp inhibitor ketoconazole compared with pomalidomide plus the CYP3A4/P-gp&#xD;
           inhibitor ketoconazole in healthy male subjects.&#xD;
&#xD;
      Part 2&#xD;
&#xD;
      1) To evaluate the pharmacokinetics of pomalidomide administered with the CYP3A4 inducer&#xD;
      carbamazepine compared with pomalidomide alone in healthy male volunteers.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      1) To evaluate the safety of pomalidomide in Part 1 and Part 2 when administered with&#xD;
      ketoconazole, fluvoxamine and/or carbamazepine.&#xD;
&#xD;
      In addition: To evaluate the safety of pomalidomide in Part 1 and Part 2 when administered&#xD;
      with ketoconazole, fluvoxamine and/or carbamazepine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-center, open label non randomized, 2-part study with 3 periods in Part&#xD;
      1, and 2 periods in Part 2. Parts 1 and 2 will be conducted in parallel. The entire study&#xD;
      will consist of a screening phase, two dosing parts, and a follow-up telephone call for&#xD;
      safety. All Periods will be separated by a washout period of at least 3 days (no more than 5&#xD;
      days) from the last pomalidomide dose to the next drug dose.&#xD;
&#xD;
      Safety will be monitored throughout the study. Safety evaluations will include adverse event&#xD;
      (AE) reporting, concomitant medications, PEs, vital sign measurements, 12-lead ECGs, and&#xD;
      clinical laboratory safety tests.&#xD;
&#xD;
      Thirty-two healthy (16 per each Part), male adult subjects 18 to 55 years of age who meet all&#xD;
      inclusion criteria and do not meet any of the exclusion criteria will be enrolled in the&#xD;
      study. Subjects enrolled in Part 1 cannot participate in Part 2 and vice versa.&#xD;
&#xD;
      Study treatments (pomalidomide, ketoconazole, fluvoxamine and carbamazepine) should be&#xD;
      administered with meals and subjects should be a served a standard meal (ie, breakfast or&#xD;
      dinner) approximately 30 minutes prior to dosing. The meal should be consumed within 30&#xD;
      minutes from serving and dosing must occur 30 minutes (Â±5 minutes) after serving the meal.&#xD;
      Subjects should be encouraged to consume the whole meal served prior to dosing. After each&#xD;
      dosing, food and beverages (except water) will be withheld from all subjects until at least 4&#xD;
      hours post dose; thereafter, subjects will be served standard meals and snacks.&#xD;
&#xD;
      For determination of plasma concentrations of pomalidomide, ketoconazole, fluvoxamine and&#xD;
      carbamazepine (and its active metabolite carbamazepine 10,11-epoxide) in each dosing regimen&#xD;
      (Period), serial blood samples will be collected.&#xD;
&#xD;
      A safety follow-up will be conducted by telephone within 4 to 7 days from the last dose. In&#xD;
      the event a subject discontinues from the study prematurely, an early termination visit will&#xD;
      be performed within 4 days following the day of discontinuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2012</start_date>
  <completion_date type="Actual">November 1, 2012</completion_date>
  <primary_completion_date type="Actual">November 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK-Cmax</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Cmax-Maximum observed concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Tmax</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Tmax: Time to maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-AUC</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>AUC-Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-(T1/2)</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>T1/2-Terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-CL/F</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>CL/F-Apparent total plasma clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Vz/F</measure>
    <time_frame>Up to 13 days</time_frame>
    <description>Vz/F: Apparent total volume of distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pomalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus Ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide plus Carbamazepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4 mg pomalidomide capsule administered orally once in the morning</description>
    <arm_group_label>Pomalidomide</arm_group_label>
    <arm_group_label>Pomalidomide plus Carbamazepine</arm_group_label>
    <arm_group_label>Pomalidomide plus Ketoconazole</arm_group_label>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
    <other_name>(CC-4047)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.</description>
    <arm_group_label>Pomalidomide plus Ketoconazole</arm_group_label>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.</description>
    <arm_group_label>Pomalidomide plus Ketoconazole plus Fluvoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>100 mg Carbamazepine tablet administered orally once in the evening on Day 1&#xD;
100 mg Carbamazepine tablet administered orally twice daily on Days 2-3&#xD;
200 mg Carbamazepine tablet administered orally twice daily on Days 4-11</description>
    <arm_group_label>Pomalidomide plus Carbamazepine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Must understand and voluntarily sign a written informed consent document (ICD) prior&#xD;
             to any study-related procedures being performed.&#xD;
&#xD;
          -  Must be able to communicate with the investigator, understand and comply with the&#xD;
             requirements of the study, and agree to adhere to restrictions and examination&#xD;
             schedules.&#xD;
&#xD;
          -  Must be a male 18 to 55 years of age (inclusive) at the time of signing the ICD, with&#xD;
             a body mass index (BMI = weight [kg]/(height [m2]) between 18 and 33 kg/m2 (inclusive)&#xD;
             and weight between 60 and 100 kg (132 to 220 lbs; inclusive)&#xD;
&#xD;
               1. For Part 1, subjects may be of any race.&#xD;
&#xD;
               2. For Part 2, subjects must be non-Asian or non-Asian descent.&#xD;
&#xD;
          -  Must be healthy (at Screening and Day -1 of Period 1) as determined by the&#xD;
             investigator on the basis of medical history, physical examination, clinical&#xD;
             laboratory safety test results, vital signs, and 12 lead electrocardiograms (ECGs).&#xD;
&#xD;
               1. Vital signs (systolic and diastolic blood pressure, pulse rate, and oral body&#xD;
                  temperature) will be assessed in the supine position after the subject has rested&#xD;
                  for at least 5 minutes.&#xD;
&#xD;
               2. Subject must be afebrile (febrile is defined as â¥ 38.5ÂºC or 101.3 Fahrenheit).&#xD;
&#xD;
               3. Systolic blood pressure in the range of 90 to 140 mmHg, diastolic blood pressure&#xD;
                  in the range of 60 to 90 mmHg, and pulse rate in the range of 45 to 100 bpm.&#xD;
&#xD;
               4. Must have a normal or clinically acceptable 12-lead ECG, with a QTcF value â¤ 430&#xD;
                  msec.&#xD;
&#xD;
               5. Clinical laboratory safety tests must be within normal limits or clinically&#xD;
                  acceptable to the Principal investigator (PI)&#xD;
&#xD;
          -  Subjects (with or without vasectomy) must agree to use barrier contraception (ie,&#xD;
             latex condom or any non-latex condom not made out of natural [animal] membrane [eg,&#xD;
             polyurethane]) and one other method (eg, spermicide) when engaging in sexual activity&#xD;
             with woman of child-bearing potential during study conduct, and for 90 days after the&#xD;
             last dose of study medication.&#xD;
&#xD;
          -  Must agree to refrain from donating blood or plasma (other than for this study) while&#xD;
             participating in this study and for at least 28 days after the last dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Similarly, must agree to refrain from donating sperm while participating in this study&#xD;
             and for at least 90 days after the last dose of study drug.&#xD;
&#xD;
          -  Will be counseled about pregnancy precautions and risks of fetal exposure and agree to&#xD;
             comply with the conditions described in the counseling document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant and relevant neurological, gastrointestinal,&#xD;
             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,&#xD;
             hematological, allergic disease, drug allergies, known hypersensitivity to a member of&#xD;
             the class of-IMIDs (immune-mediated inflammatory diseases), or other major disorders&#xD;
&#xD;
          -  Any significant medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from participating in the study.&#xD;
&#xD;
          -  Any condition including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he were to participate in the study.&#xD;
&#xD;
          -  Any condition that confounds the ability to interpret data from the study.&#xD;
&#xD;
          -  Used any prescribed systemic or topical medication within 30 days of the first dose&#xD;
             administration, unless Sponsor agreement is obtained.&#xD;
&#xD;
          -  Used any non-prescribed systemic or topical medication (including vitamin/mineral&#xD;
             supplements, and herbal medicines) within 14 days of the first dose administration,&#xD;
             unless Sponsor agreement is obtained.&#xD;
&#xD;
          -  Has any surgical or medical conditions possibly affecting drug absorption,&#xD;
             distribution, metabolism and excretion (ADME), eg, bariatric procedure.&#xD;
&#xD;
          -  Donated blood or plasma within 8 weeks before the first dose administration to a blood&#xD;
             bank or blood donation center.&#xD;
&#xD;
          -  History of drug abuse (as defined by the current version of the Diagnostic and&#xD;
             Statistical Manual within 2 years before dosing, or positive drug screening test&#xD;
             reflecting consumption of illicit drugs.&#xD;
&#xD;
          -  History of alcohol abuse (as defined by the current version of the DSM) within 2 years&#xD;
             before dosing, or positive alcohol screen.&#xD;
&#xD;
          -  Known to have, or tests positive for, active or chronic hepatitis B, hepatitis C, or&#xD;
             HIV antibodies.&#xD;
&#xD;
          -  Exposed to an investigational drug (new chemical entity) within 60 days preceding the&#xD;
             first dose administration, or 5 half-lives of that investigational drug, if known&#xD;
             (whichever is longer).&#xD;
&#xD;
          -  Received vaccination (excluding seasonal flu vaccination) within 90 days of the study&#xD;
             drug administration.&#xD;
&#xD;
          -  Smokes more than 10 cigarettes, or consumes the equivalent in tobacco, per day.&#xD;
&#xD;
          -  Subjects who are part of the staff personnel or family members of the investigational&#xD;
             study staff.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Palmisano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Research Unit, Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.</citation>
    <PMID>30262659</PMID>
  </reference>
  <reference>
    <citation>Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027.</citation>
    <PMID>30792190</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-4047</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Ketoconazole</keyword>
  <keyword>Fluvoxamine</keyword>
  <keyword>Carbamazepine</keyword>
  <keyword>DDI</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

